Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Board Authorizes Share Repurchase Program, Dividend

NEW YORK (GenomeWeb News) – Agilent Technologies today said that its board of directors has authorized a new share repurchase program, which will become effective following the completion of its existing $1 billion share repurchase program.

The firm didn't say how much it expects to spend on the new repurchase program but stated that the goal is to "reduce or eliminate dilution resulting from issuances of stock under the company's employee equity incentive programs to maintain a share count of approximately 335 million diluted shares."

The board also authorized a 10 percent increase in the firm's quarterly dividend to $.132 per share. The dividend will be paid on Jan. 22, 2014, to all stockholders of record as of the close of business on Dec. 31, 2013.

Last week Agilent reported that its fourth quarter revenues fell 3 percent year over year, but still beat analysts' estimates on the top and bottom lines. For FY 2013 its revenues dropped 1 percent.

Agilent announced in September that it would split into two publicly traded companies, one focused on its life science and diagnostics business, the other on its electronic measurement business. That split is expected to be completed in November 2014.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.